Compare MSD & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | STXS |
|---|---|---|
| Founded | 1993 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 139.3M |
| IPO Year | N/A | 2004 |
| Metric | MSD | STXS |
|---|---|---|
| Price | $6.91 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 56.4K | ★ 481.1K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.91 | $1.24 |
| 52 Week High | $7.94 | $3.59 |
| Indicator | MSD | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 53.65 |
| Support Level | $6.91 | $1.28 |
| Resistance Level | $7.44 | $1.51 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.40 | 87.97 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.